Pitavastatin
Brand names: Livalo (pitavastatin calcium), Zypitamag (pitavastatin magnesium)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Primary hyperlipidaemia | Adults | Adjunctive to diet | FDA Approved |
| Heterozygous familial hypercholesterolaemia (heFH) | Adults and paediatric patients ≥8 years | Adjunctive to diet | FDA Approved |
Pitavastatin was approved by the FDA in 2009 and is the most recently introduced statin to the US market. The 2018 AHA/ACC cholesterol guideline classifies pitavastatin 2–4 mg as moderate-intensity statin therapy (expected ~30–45% LDL-C reduction). A key clinical advantage is its minimal cytochrome P450 metabolism, which makes it particularly suitable for patients on complex drug regimens, including those receiving antiretroviral therapy for HIV. The landmark REPRIEVE trial (NEJM 2023) demonstrated a 35% reduction in major adverse cardiovascular events with pitavastatin 4 mg in people living with HIV, establishing its role in primary CV prevention for this population.
Primary CV prevention in people living with HIV: The REPRIEVE trial (7,769 participants, NEJM 2023) showed a 35% MACE reduction with pitavastatin 4 mg. DHHS guidelines now recommend statin therapy for this population. Pitavastatin was chosen specifically because it does not interact with antiretrovirals via CYP3A4 (Evidence quality: High — RCT).
Statin-intolerant patients: Some data suggest pitavastatin may be tolerated by patients who have experienced myalgia with other statins, though this is not well-established in large trials (Evidence quality: Low).
Dosing
Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Primary hyperlipidaemia — standard initiation | 2 mg once daily | 2–4 mg once daily | 4 mg/day | Take at same time each day with or without food Assess LDL-C as early as 4 weeks; titrate if needed |
| Primary CV prevention in HIV (REPRIEVE protocol) | 4 mg once daily | 4 mg once daily | 4 mg/day | Selected for minimal interaction with ART REPRIEVE used pitavastatin calcium 4 mg; no dose titration |
| Patient needing low-intensity therapy or initial tolerability assessment | 1 mg once daily | 1–2 mg once daily | 4 mg/day | Consider for patients previously intolerant of other statins |
| Co-administration with erythromycin | 1 mg once daily | 1 mg once daily | 1 mg/day | Erythromycin increases pitavastatin AUC ~2.8-fold (FDA PI) |
| Co-administration with rifampin | 1 mg once daily | 1–2 mg once daily | 2 mg/day | Rifampin increases pitavastatin peak exposure (FDA PI) |
| Moderate renal impairment (eGFR 30–59) or ESRD on haemodialysis | 1 mg once daily | 1–2 mg once daily | 2 mg/day | AUC ~2-fold higher in moderate renal impairment; ~86% higher in ESRD Haemodialysis does not clear pitavastatin due to >99% protein binding; severe impairment (eGFR 15–29) shows less exposure increase (~36%) |
Paediatric Dosing (heFH, ≥8 years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Heterozygous familial hypercholesterolaemia | 2 mg once daily | 2–4 mg once daily | 4 mg/day | Dose-dependent increase in plasma concentrations at 2 and 4 mg Titrate at 4-week intervals based on LDL-C response |
Unlike lovastatin, simvastatin, and to some extent atorvastatin, pitavastatin is not significantly metabolised by CYP3A4. Its primary metabolic pathway is glucuronidation via UGT enzymes, with only minor involvement of CYP2C9 and CYP2C8. This means pitavastatin can be used safely with potent CYP3A4 inhibitors such as HIV protease inhibitors, azole antifungals, and macrolide antibiotics (except erythromycin, which increases pitavastatin exposure through a transporter-mediated mechanism). The maximum recommended dose is 4 mg/day; doses above this were associated with increased myopathy risk in premarketing studies.
Pharmacology
Mechanism of Action
Pitavastatin is a synthetic HMG-CoA reductase inhibitor that competitively blocks the conversion of HMG-CoA to mevalonate, the rate-limiting step in hepatic cholesterol biosynthesis. By depleting intracellular cholesterol, pitavastatin upregulates LDL receptor expression on hepatocyte surfaces, accelerating clearance of LDL-C from the circulation. It also reduces VLDL production and has favourable effects on HDL-C, with some evidence suggesting more robust HDL raising compared to other statins at equivalent LDL-lowering doses. Pitavastatin contains a cyclopropyl group in its structure that confers metabolic stability and resistance to CYP3A4-mediated breakdown. Beyond lipid effects, the REPRIEVE trial demonstrated that pitavastatin reduces coronary plaque progression and arterial inflammation in people living with HIV.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax ~1 h; absolute bioavailability 51% (oral solution); absorbed mainly in small intestine | Highest bioavailability and fastest Tmax of all statins; high-fat meal decreases Cmax by 43% but does not significantly affect AUC |
| Distribution | Protein binding >99% (albumin, alpha-1 acid glycoprotein); Vd 148 L | Extensive protein binding; haemodialysis ineffective for removal |
| Metabolism | Primarily UGT1A3/UGT2B7 (lactonization); minimal CYP2C9 and CYP2C8; not significantly metabolised by CYP3A4; OATP1B1 substrate | Major advantage: CYP3A4 inhibitors do not significantly alter exposure; erythromycin increases AUC ~2.8-fold via transporter inhibition; OATP1B1 polymorphisms may affect levels |
| Elimination | t½ ~12 h; 79% faeces, 15% urine | Longer half-life than lovastatin/fluvastatin; can be dosed at any time of day (morning or evening) |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Myalgia | 1.5–3.1% | Dose-related; most common cause of discontinuation at 4 mg (0.5%) |
| Constipation | 1.5–3.6% | Dose-related; higher at 4 mg; increase dietary fibre and fluid intake |
| Back pain | 1.5–2.6% | Not dose-related; comparable to placebo in some dose groups |
| Diarrhea | 1.5–2.6% | Usually mild and self-limiting |
| Pain in extremity | 0.6–2.1% | Dose-related; higher at 4 mg; distinguish from myopathy symptoms |
| Headache | 1–2% | Reported in clinical trials; typically transient |
| Influenza | 1–2% | Reported in clinical trials; not clearly drug-related |
| Nasopharyngitis | 1–2% | Reported in clinical trials; not clearly drug-related |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myopathy / Rhabdomyolysis | Rare; risk increases >4 mg/day | Weeks to months; dose-dependent | Discontinue immediately; check CK and renal function; doses >4 mg associated with increased severe myopathy in premarketing studies |
| Immune-mediated necrotising myopathy (IMNM) | Very rare (post-marketing) | Months to years; persists after discontinuation | Discontinue; anti-HMG-CoA reductase antibody testing; rheumatology referral; immunosuppressive therapy may be needed |
| Hepatotoxicity | Rare (post-marketing reports including fatal cases) | Variable | Stop pitavastatin; investigate alternative aetiologies; do not rechallenge if serious liver injury confirmed |
| New-onset diabetes mellitus | Uncommon (class effect) | Months to years | Continue statin (CV benefit outweighs risk); manage diabetes per guidelines; HbA1c and fasting glucose elevations reported |
| Hypersensitivity reactions (rash, pruritus, urticaria, angioedema) | Rare | Variable | Discontinue if significant; emergency treatment for angioedema |
| Interstitial lung disease | Very rare (post-marketing) | Variable | Discontinue; specialist referral; reported with several statins as class effect |
Dosages of pitavastatin greater than 4 mg once daily were associated with an increased risk of severe myopathy in premarketing clinical studies. The maximum recommended dose is therefore 4 mg daily. For patients requiring higher-intensity LDL-C lowering beyond what pitavastatin 4 mg can achieve, the FDA PI recommends prescribing an alternative LDL-C-lowering treatment rather than exceeding this dose cap.
Drug Interactions
Pitavastatin is primarily metabolised by glucuronidation (UGT1A3/UGT2B7), not by cytochrome P450 enzymes. It is an OATP1B1 substrate, which is the main transporter-mediated route of hepatic uptake. Because CYP3A4 plays no significant role in pitavastatin metabolism, many common drug interactions seen with lovastatin and simvastatin do not apply. However, drugs that inhibit OATP1B1 (such as cyclosporine) can substantially increase pitavastatin exposure.
Pitavastatin was specifically chosen for the REPRIEVE trial because it does not interact with antiretroviral drugs via CYP3A4. This gives it a unique position among statins for use in people living with HIV, where protease inhibitors, NNRTIs, and pharmacokinetic boosters (ritonavir, cobicistat) would significantly increase the exposure of CYP3A4-dependent statins like lovastatin and simvastatin.
Monitoring
- Lipid PanelBaseline, as early as 4 weeks, then periodically
RoutineFasting lipid profile (LDL-C, HDL-C, Total-C, TG). Adjust dose if LDL-C goal not achieved at 4 weeks. For patients unable to reach goal on 4 mg, prescribe alternative therapy. - Liver Enzymes (ALT/AST)Before initiation; as clinically indicated
RoutineObtain baseline transaminases. Repeat if symptoms of liver injury develop (fatigue, anorexia, jaundice, dark urine). Rare post-marketing reports of fatal and non-fatal hepatic failure. - Creatine Kinase (CK)When clinically indicated
Trigger-basedMeasure if patient reports unexplained muscle pain, tenderness, or weakness. CK elevation (0.6% at 4 mg) was the most common lab reason for discontinuation in trials. - Fasting Glucose / HbA1cBaseline; periodically in at-risk patients
RoutineHbA1c and fasting glucose elevations reported with pitavastatin (class effect). Monitor for new-onset diabetes in patients with metabolic risk factors. - Renal FunctionBaseline; if rhabdomyolysis suspected
Trigger-basedAssess eGFR before starting to guide dose selection. AUC approximately doubles in moderate renal impairment (eGFR 30–59) and is 86% higher in ESRD — start 1 mg and cap at 2 mg/day for these populations.
Contraindications & Cautions
Absolute Contraindications
- Concomitant use of cyclosporine — significantly increases pitavastatin exposure
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to pitavastatin or any excipient (angioedema, rash, pruritus, urticaria reported)
- Pregnancy — may cause fetal harm; discontinue when pregnancy recognised
- Breastfeeding — not recommended based on mechanism of action
Relative Contraindications (Specialist Input Recommended)
- Moderate hepatic impairment (Child-Pugh B) — AUC 3.8-fold and Cmax 2.7-fold higher; half-life increases to ~15 h; use only with close monitoring
- Moderate renal impairment (eGFR 30–59) or ESRD on haemodialysis at doses >2 mg/day — AUC up to ~2-fold higher; start 1 mg, max 2 mg per FDA PI
- History of statin-associated myopathy or IMNM
Use with Caution
- Elderly patients (≥65 years) — predisposing factor for myopathy; PK shows ~30% higher AUC vs younger adults
- Uncontrolled hypothyroidism — correct before starting therapy
- Concomitant erythromycin — cap at 1 mg/day
- Concomitant rifampin — cap at 2 mg/day
- Major surgery or conditions predisposing to rhabdomyolysis (sepsis, hypotension, trauma) — consider temporary discontinuation
All statins carry the risk of myopathy, defined as muscle pain or weakness with CK >10× ULN. In rare cases, rhabdomyolysis with acute renal failure can occur, which may be fatal. For pitavastatin specifically, doses greater than 4 mg/day were associated with increased risk of severe myopathy in premarketing studies. Risk factors include advanced age (≥65), renal impairment, uncontrolled hypothyroidism, and concomitant use of drugs that increase pitavastatin exposure (cyclosporine is contraindicated; erythromycin and rifampin require dose caps).
Patient Counselling
Purpose of Therapy
Pitavastatin helps lower cholesterol levels in the blood, which reduces the risk of heart attack, stroke, and other cardiovascular events. For people living with HIV, pitavastatin has been shown to reduce the risk of heart disease beyond what cholesterol lowering alone would predict. It works best when combined with a heart-healthy diet, regular physical activity, and weight management.
How to Take
Take pitavastatin once daily at the same time each day, with or without food. It can be taken in the morning or evening. Swallow the tablet whole. Do not use cyclosporine while taking pitavastatin. The maximum dose is 4 mg daily.
Sources
- LIVALO (pitavastatin calcium) tablets — Full Prescribing Information. Kowa Pharmaceuticals America, Inc. Revised January 2024. FDA DailyMedPrimary reference for dosing, PK, drug interactions, adverse reactions, contraindications, and the 4 mg dose ceiling.
- ZYPITAMAG (pitavastatin magnesium) tablets — Prescribing Information. Medicure Inc. Revised January 2024. DailyMedGeneric pitavastatin magnesium salt label with updated IMNM and hypersensitivity post-marketing data.
- Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection (REPRIEVE). N Engl J Med. 2023;389(8):687-699. doi:10.1056/NEJMoa2304146Landmark 7,769-patient RCT demonstrating 35% reduction in MACE with pitavastatin 4 mg in people living with HIV over median 5.1 years; stopped early for efficacy.
- Grinspoon SK, Fitch KV, Zanni MV, et al. Trial Update of Pitavastatin to Prevent Cardiovascular Events in HIV Infection. N Engl J Med. 2024;391(14):1375-1377. doi:10.1056/NEJMc2400870Updated REPRIEVE analysis confirming consistent efficacy over 5.6 years follow-up with NNT of 100; led to revised DHHS treatment guidelines.
- Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4:291-302.Active-controlled non-inferiority trial comparing pitavastatin 4 mg to atorvastatin 20 mg for LDL-C lowering efficacy.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003Current US cholesterol guideline classifying pitavastatin 2–4 mg as moderate-intensity statin therapy.
- Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e52-e81. doi:10.1161/ATV.0000000000000073Comprehensive AHA review of statin class safety including myopathy risk factors and metabolic effects.
- Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34(7):1229-1236. doi:10.1124/dmd.106.009290Key study demonstrating OATP1B1-mediated hepatic uptake of pitavastatin and the transporter basis for drug interactions.
- Freiberg MS. HIV and Cardiovascular Disease — An Ounce of Prevention. N Engl J Med. 2023;389(8):760-761. doi:10.1056/NEJMe2306778Editorial accompanying REPRIEVE discussing the significance of statin therapy for CV prevention in HIV.
- Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705. doi:10.1111/j.1476-5381.2009.00430.xReview of OATP transporter pharmacology relevant to pitavastatin hepatic uptake and drug interaction mechanisms.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NIDDK. Pitavastatin. NCBI BookshelfNIH resource on pitavastatin hepatotoxicity patterns and rare post-marketing hepatic failure reports.
- Kolossváry M, Schnittman SR, Zanni MV, et al. Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial. JAMA Cardiol. 2024;9(4):367-377. doi:10.1001/jamacardio.2024.0069REPRIEVE mechanistic substudy showing pitavastatin reduces coronary plaque progression and upregulates procollagen pathways.